Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 226 to 240 of 535 results for physical activity

  1. Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)

    Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.

  2. Infliximab for treating moderate to severe plaque psoriasis (TA134)

    Evidence-based recommendations on infliximab for treating moderate to severe psoriasis in adults.

  3. Upadacitinib for treating moderate rheumatoid arthritis (TA744)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.

  4. Drug misuse prevention: targeted interventions (NG64)

    This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.

  5. Partial replacement of the meniscus of the knee using a biodegradable scaffold (HTG289)

    Evidence-based recommendations on partial replacement of the meniscus of the knee using a biodegradable scaffold. This involves placing a biodegradable implant into the meniscus to support regrowth and repair of the damage.

  6. Antenatal and postnatal mental health (QS115)

    This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.

  7. Methods for the development of NICE public health guidance (third edition) (PMG4)

    This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance

  8. How do individual and local factors influence the effectiveness of specific approaches to encouraging walking or cycling?

    planning? Source guidance details Comes from guidance Physical activity: walking and cycling Number PH41 Date issued

  9. Lifestyle factors to reduce the risk of pelvic floor dysfunction: What lifestyle factors reduce the risk of developing pelvic floor dysfunction (diet, reducing carbonated drink and caffeine intake)?

    made the recommendation for research, see the rationale section on physical activity and diet and other modifiable risk factors. Full...

  10. Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

    Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.

  11. FreeStyle Libre for glucose monitoring (MIB110)

    NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .

  12. Secukinumab for treating active ankylosing spondylitis (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis.

  13. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)

    Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.

  14. How could existing guidance on evaluating complex, population-wide interventions be most usefully adapted and applied to approaches that aim to increase rates of walking and cycling?

    regeneration. Source guidance details Comes from guidance Physical activity: walking and cycling Number PH41 Date issued

  15. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.